Acura extends debt maturity and LTX-03 NDA deadline to Dec 31, 2025; warns of cash crunch

ACURA PHARMACEUTICALS, INC

Principal balance on AD Pharma promissory note $7,994,279 plus ~$683,000 accrued interest as of May 29, 2025.
Maturity of note extended from May 31, 2025 to December 31, 2025.
FDA NDA acceptance deadline for LTX-03 (hydrocodone/APAP) extended from May 31, 2025 to December 31, 2025 per Amendment #12.
Warrant to purchase 10M shares at $0.01 also extended to expire Dec 31, 2025.
Company states without additional financing by mid-June 2025 it will shut down or seek bankruptcy, risking total loss of shareholder value.

item 1.01item 2.01item 2.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.